Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

Trial Profile

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Pidilizumab (Primary) ; Dendritic cell vaccines
  • Indications Multiple myeloma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 08 Dec 2015 Results (n=22) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 22 Nov 2013 Planned end date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 25 Jun 2013 Planned end date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top